Compass Therapeutics financials
$1.10−0.90%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $850.0K | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $850.0K | $0.00 | $0.00 | — | — |
| Gross margin | — | 100.0% | — | — | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M | -$27.8M |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M | -$29.5M |
| Net margin | — | −5808.8% | — | — | — | — |
| Diluted EPS | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 | $-0.96 |
| EBITDA | -$72.6M | -$56.0M | -$49.7M | -$39.8M | -$81.3M | -$25.4M |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M | -$26.8M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M | -$26.9M |
| Diluted shares | 157.7M | 137.4M | 127.0M | 105.2M | 62.9M | 30.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M | $47.1M |
| Short-term investments | $178.3M | $83.2M | $128.2M | $151.7M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.3M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M | $51.9M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M | $12.0M |
| Shareholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M | $39.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology